Are these former FTSE 100 shares now brilliant contrarian buys?

Let’s look at the bounce-back chances of two former FTSE 100 (INDEXFTSE: UKX) shares.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With global healthcare investment set to continue steadily rising in the years ahead, I reckon ConvaTec Group (LSE: CTEC) could prove a terrific growth stock.

The medical products and technologies company — a leader in wound care and continence products — fell out of the FTSE 100 in November in the wake of a disastrous trading update the previous month.

Back then, ConvaTec chopped down its full-year revenues forecasts on the back of disappointing performances from its new products, in addition to supply delays, the latter predicted to cancel out previous margin improvements. The firm printed a painful daily share price loss of 28% on the back of the news.

The business failed to snap back until Thursday’s bright, full-year trading statement, the share last trading 8% higher and at four-month peaks. I reckon this could prove a significant moment in the company’s investment story.

Bag it up

ConvaTec declared today that while the impact of the aforementioned supply problems will seep over into the current year, sales managed to beat expectations last year.

Group revenues rose 4.5% in 2017 to $1.76bn, although this was not enough to stop adjusted pre-tax profit from falling 3.3% year-on-year to $456.8m. ConvaTec attributed the result to “increased investment in growth” on top of the cost of listing the company in 2016.

Investors cheered news that revenues on an organic basis rose 2.3% in the last fiscal period, beating the company’s revised predictions of a 1-2% advance put out last year.

But ConvaTec is predicted to see earnings expansion cool from recent years. That’s due, in part, to lost orders related to last year’s supply problems as well as the firm’s attempts to tackle the resultant backlogs, both of which will continue during the first half of 2018, it noted.

That said, a predicted 14% rise for 2018 is nothing to be scoffed at. And the medical mammoth is expected to print a further 9% advance next year.

In my opinion, ConvaTec’s long-term profits outlook remains a compelling one and last year’s manufacturing problems, also in my opinion, will represent nothing more than a bump in the road.

I reckon a forward P/E ratio of 15 times represents an attractive level at which to tap into the FTSE 250 firm’s compelling earnings picture.

Not such a hot stock…

I’m not so optimistic over the earnings prospects of Merlin Entertainments (LSE: MERL).

The Alton Towers owner — which was also kicked out of Britain’s blue chip index at the end of last year — has fallen out of favour with share pickers. That came after announcing in October that like-for-like revenues had flatlined during the 40 weeks to October 7 due to “the series of terror attacks and unfavourable weather” during the period.

These troubles have led City analysts to predict that Merlin’s earnings will have fallen 3% in 2017, a rare dip if realised.

Now while City analysts are predicting that Merlin will return to earnings growth straight away (rises of 5% and 10% are estimated for 2018 and 2019, respectively), I’m not convinced as the issues that were prevalent in 2017 are in danger of continuing for much longer.

And I believe a prospective P/E ratio of 15.9 times is a little too high given these problems.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£3,000 in savings? Here’s how I’d use that to start earning a monthly passive income

Our writer digs into the details of how spending a few thousand pounds on dividend shares now could help him…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BP share price in the next three years

I can understand why the BP share price is low, as oil's increasingly seen as evil. But BP's a cash…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

This FTSE 100 Dividend Aristocrat is on sale now

Stephen Wright thinks Croda International’s impressive dividend record means it could be the best FTSE 100 stock to add to…

Read more »

Investing Articles

3 shares I’d buy for passive income if I was retiring early

Roland Head profiles three FTSE 350 dividend shares he’d like to buy for their passive income to support an early…

Read more »

Investing Articles

Here’s how many Aviva shares I’d need for £1,000 a year in passive income

Our writer has been buying shares of this FTSE 100 insurer, but how many would he need to aim for…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

1 incredible growth stock I can’t find on the FTSE 100

The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With an £8K lump sum, I could create an annual second income worth £5,347

This Fool explains how a second income is achievable by using a lump sum, investing in stocks, and the magic…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BT share price in the next 3 years

With the BT share price down so low, the dividend looks very nice indeed. The company's debt is off-putting, though.…

Read more »